Close Menu

NEW YORK – NanoString Technologies reported after the close of the market on Wednesday that its second quarter revenues were down 25 percent year over year, driven by lower consumables and collaboration revenues.

For the three months ended June 30, 2020 the company's total revenues were $22.6 million compared to $30.3 million a year ago, beating the consensus Wall Street estimate of $16.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.